Vascular endothelial growth factor (VEGF) is also known as vascular permeability factor or vasculotropin. It is a 46kDa homodimeric peptide growth factor. This gene is located on human chromosome 13q12.
Immunogen
The antiserum was produced against synthesized peptide derived from human VEGFR1 around the phosphorylation site of Tyr1333.
Immunogen Range: 1289-1338
Application
Anti-phospho-VEGFR1 (pTyr1333) antibody has been used in immunostaining.
Biochem/physiol Actions
Vascular endothelial growth factor (VEGF) activates endothelial cell growth in vitro and angiogenesis in vivo by binding to endothelial cells. This protein participates in endothelial proliferation, regulation of vascular permeability and thrombogenicity.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Interfering with interactions of vascular endothelial growth factors (VEGFs) with their receptors (VEGFRs) effectively inhibits angiogenesis and tumor growth. We designed an antagonist peptide of VEGF-A and VEGF-B reproducing two discontinuous receptor binding regions of VEGF-B (loop 1 and loop3)
Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1
Molecular medicine reports, 17(3), 4581-4588 (2018-01-13)
Liver cancer is a globally prevalent cancer with poor prognosis. The present study investigated the link between microRNA-378a (miR‑378a) expression and the sensitivity of hepatocellular carcinoma (HCC) and hepatoblastoma (HB) cancers to sorafenib therapy. miR‑378a expression was determined in liver
The genetic differences between gallbladder and bile duct cancer cell lines
Saito S, et al.
Oncology Reports, 16(5), 949-956 (2006)
VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.